Tobira Therapeutics, Inc. (TBRA) Set to be Acquired by Allergan (AGN) as Cenicriviroc Approaches Phase III Development
Tobira Therapeutics, Inc. (NASDAQ: TBRA) is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for non-alcoholic steatohepatitis (NASH) and other liver diseases. The company’s lead product candidate, cenicriviroc (CVC), is a dual inhibitor of the CCR2 and CCR5 pathways currently being evaluated for the treatment of NASH in adults with liver fibrosis and primary sclerosing cholangitis (PSC). Tobira is currently on track to complete planning for phase III trials of CVC by the end of 2016, according to an update issued last month, after topline data from the company’s CENTAUR phase IIb study demonstrated a “clinically…







